Enhanced Genomics and The ALBORADA Drug Discovery Institute partner to accelerate Alzheimer’s drug discovery
- Enhanced Genomics’ 3D multi-omics platform harnessed to rapidly identify multiple novel therapeutic targets that were undetectable using conventional genomic approaches
- Breakthrough demonstrates the potential of 3D multi-omics to revolutionize drug discovery timelines and success rates across various disease areas
Cambridge, UK, 24th June 2025: Enhanced Genomics (‘Enhanced’ or ‘the Company’), the biotechnology company pioneering 3D multi-omics to rapidly identify high-confidence, genetically validated drug targets for common diseases, today announced a strategic partnership with The ALBORADA Drug Discovery Institute at the University of Cambridge. Funded by Alzheimer’s Research UK, The ALBORADA Drug Discovery Institute is developing the next generation of treatments for the diseases that cause dementia. The partnership has already yielded novel drug targets for Alzheimer’s disease, demonstrating the potential of 3D multi-omics to vastly reduce drug-discovery timelines and increase success rates across various disease areas.
Under the partnership agreement, Enhanced utilized its proprietary Promoter Capture Hi-C technology, multi-omic data, and expert knowledge to map long-range chromatin interactions, revealing crucial gene regulatory-mechanisms involved in driving Alzheimer’s disease. This approach identified several novel targets, as well as corroborating targets already reported in the literature, opening new avenues for therapeutic intervention.
“Our partnership with The ALBORADA Drug Discovery Institute showcases the transformative power of 3D multi-omics in drug discovery,” said Dr. Dan Turner, CSO of Enhanced Genomics. “By harnessing our unique platform, we have not only accelerated the target discovery process but also unveiled new therapeutic possibilities by harnessing the full potential of the non-coding genome. We’re confident that we can improve both timescales and success rates of target ID and drug development using 3D multi-omics.”
Dr. John Skidmore, CSO at The ALBORADA Drug Discovery Institute, added: “Using the insights provided by Enhanced’s technology, we have gained new actionable targets operating by a range of mechanisms. This could significantly advance our ability to develop effective treatments for Alzheimer’s disease.”
Dr. Julia Dudley, Head of Strategic Programmes at Alzheimer’s Research UK, said: “There has been unprecedented progress in dementia drug development, but we must keep up the momentum to help find new treatments and, in time, a cure. We are delighted that The ALBORADA Drug Discovery Institute and Enhanced Genomics have joined forces to accelerate the dementia drug discovery process. Partnerships like these are bringing the worlds of academia and industry closer together, helping to speed up the discovery of potential new treatments that people with dementia so desperately need.”
Enhanced Genomics and The ALBORADA Drug Discovery Institute are now exploring opportunities to expand their partnership to other neurodegenerative diseases. The company is also open to partnerships with pharmaceutical and biotech firms interested in utilizing its 3D multi omics platform in their own drug discovery programs.
For more information please visit: enhancedgenomics.com
ENDS
For further information, please contact:
Zyme Communications
Katie Odgaard
Tel: +44(0)7787 502 947
Email: katie.odgaard@zymecommunications.com
To opt out from receiving press releases from Zyme Communications please email info@zymecommunications.com. To view our privacy policy please click here.
About Enhanced Genomics
Enhanced Genomics (www.enhancedgenomics.com) is the only biotechnology company able to define causal biology from disease-associated variants on a genome-wide scale, enabling the rapid identification of new, high-confidence, first-in-class therapeutic targets for common diseases, with blockbuster potential.
Unlocking decades worth of genetic data and providing unparalleled validation via its proprietary 3D multi-omics platform and data-rich human cell type-specific atlas, the Company is able to expedite drug discovery and precision medicine.
Enhanced’s 3D multi-omics platform is the only genome-wide, hypothesis-free technology able to translate massive amounts of disease-associated variant data into causal biology on a cell-type-specific basis. This approach supports both target prioritization, more than doubling the probability of success, and target identification, vastly increasing the number of novel disease targets that can be identified, more efficiently and in a fraction of the time previously possible. It also allows the stratification of patients into responder groups to improve and accelerate clinical trials.
Enhanced Genomics has an active in-house target discovery and development program, focusing on common diseases with large unmet needs. The Company also welcomes enquiries from potential partners looking to enable and accelerate their discovery and development initiatives.
Follow Enhanced Genomics on LinkedIn and BlueSky.
About The ALBORADA Drug Discovery Institute
The ALBORADA Drug Discovery Institute, established by Alzheimer’s Research UK, is developing new approaches to slow or halt the progress of the diseases that cause dementia. The Institute explores mechanisms of proteostasis associated with the misfolded, aggregated proteins which characterise most neurodegenerative diseases and also downstream mechanisms such as inflammation.
About Alzheimer’s Research UK
Alzheimer’s Research UK is the UK’s leading dementia research charity; our vision is a world free from the fear, harm, and heartbreak of dementia.
We fund life-changing research, influence government and policymakers, and provide information for people affected by dementia. Our mission is to accelerate progress towards a cure for dementia, by revolutionising the way we treat, diagnose, and prevent the condition.
Since the charity was founded in 1992, we have invested more than £188m in dementia research, helping fuel drug discovery, improve diagnostics and further our understanding of the genetics of the disease. Last year we invested more than £28m in our charitable activities, including £23m in research.
You can support Alzheimer’s Research UK by donating, fundraising, volunteering and campaigning. To find out more about the charity and how you can help visit www.alzheimersresearchuk.org or call 0300 111 5555. Follow us on X, Facebook, Instagram, LinkedIn and TikTok.
